CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS

27.11.2020 16:20:00 CET | GlobeNewswire

Bid procedure, 2020-12-04
Bonds	SWEDEN I/L BOND: 3108, SE0004211084, 2022-06-01 SWEDEN I/L BOND: 3109, SE0005703550, 2025-06-01
Bid date	2020-12-04
Bid times	09.00-10.00 (CET/CEST) on the Bid date
Requested volume (corresponding nominal amount)	3108: 500 mln SEK +/-250 mln SEK 3109: 500 mln SEK +/-250 mln SEK Maximum 1000 mln in total
Highest permitted bid volume (corresponding nominal amount)	3108: 500 mln SEK per bid 3109: 500 mln SEK per bid
Lowest permitted bid volume (corresponding nominal amount)	SEK 50 million per bid
Expected allocation time	No later than 10.10 (CET/CEST) on the Bid date
Delivery and payment date	2020-12-08
Delivery of bonds	To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383

Stockholm, 2020-11-27

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

About GlobeNewswire

GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform22.1.2021 14:00:00 CET | Press release

Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide. BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more efficient

Corr: SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 13:23:24 CET | Press release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Korr: SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 13:23:24 CET | Pressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

PCI Biotech to present at RNA Therapeutics Virtual Conference22.1.2021 12:04:15 CET | Press release

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event. On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies. The presentation slides will be made available t

RESULT OF SEK TENDER OPERATION FOR ONWARD LENDING22.1.2021 11:30:00 CET | Press release

AuctionAuction resultsAuction date2021-01-22Settlement date2021-01-26Final repayment date2025-01-27Offered volume, SEK bn50Total bid amount, SEK bn0Number of bids0Alloted volume, SEK bn0Interest rateRepo rateAdditional interest rate, %0.10